Peptide YY inhibits pancreatic secretion by inhibiting cholecystokinin release in the dog

Felix Lluis, Guillermo Gomez, Masaki Fujimura, George H. Greeley, James C. Thompson

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

Peptide YY inhibits the pancreatic exocrine secretion (bicarbonate, water, and protein) that is stimulated by cholecystokinin, secretin, or neurotensin in the dog, but whether peptide YY inhibits the release of gut peptides that stimulate pancreatic exocrine secretion is not known. Six dogs were prepared with gastric, pancreatic, and cecal cannulas. On separate days, a single dose of sodium oleate (3, 6, 7.5, 9, 12, 15, or 18 mmol/h) was given intraduodenally for 90 min, either alone (control) or in combination with peptide YY (25, 50, 100, 200, or 400 pmol/kg · h, i.v.). We measured plasma levels of cholecystokinin- 33 39, secretin, neurotensin, and peptide YY by radioimmunoassay. During infusion of peptide YY, the integrated release of cholecystokinin (3.3 ± 0.5 ng-[0-90] min/ml) was decreased significantly (p < 0.05) when compared with control values (5.6 ± 0.6). Release of secretin and neurotensin was not affected. A positive correlation (p < 0.05) was found between the release of cholecystokinin and pancreatic protein output in both control (r = 0.68) and peptide YY-treated (r = 0.67) groups. Release of peptide YY was significant after intraduodenal or intracolonic administration of sodium oleate. These studies demonstrate that inhibition of pancreatic protein secretion by peptide YY in dogs is mediated, at least in part, by an inhibition of the release of cholecystokinin.

Original languageEnglish (US)
Pages (from-to)137-144
Number of pages8
JournalGastroenterology
Volume94
Issue number1
StatePublished - 1988
Externally publishedYes

Fingerprint

Peptide YY
Cholecystokinin
Dogs
Neurotensin
Secretin
Proteins
Bicarbonates
Radioimmunoassay
Stomach
Peptides
Water

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Lluis, F., Gomez, G., Fujimura, M., Greeley, G. H., & Thompson, J. C. (1988). Peptide YY inhibits pancreatic secretion by inhibiting cholecystokinin release in the dog. Gastroenterology, 94(1), 137-144.

Peptide YY inhibits pancreatic secretion by inhibiting cholecystokinin release in the dog. / Lluis, Felix; Gomez, Guillermo; Fujimura, Masaki; Greeley, George H.; Thompson, James C.

In: Gastroenterology, Vol. 94, No. 1, 1988, p. 137-144.

Research output: Contribution to journalArticle

Lluis, F, Gomez, G, Fujimura, M, Greeley, GH & Thompson, JC 1988, 'Peptide YY inhibits pancreatic secretion by inhibiting cholecystokinin release in the dog', Gastroenterology, vol. 94, no. 1, pp. 137-144.
Lluis F, Gomez G, Fujimura M, Greeley GH, Thompson JC. Peptide YY inhibits pancreatic secretion by inhibiting cholecystokinin release in the dog. Gastroenterology. 1988;94(1):137-144.
Lluis, Felix ; Gomez, Guillermo ; Fujimura, Masaki ; Greeley, George H. ; Thompson, James C. / Peptide YY inhibits pancreatic secretion by inhibiting cholecystokinin release in the dog. In: Gastroenterology. 1988 ; Vol. 94, No. 1. pp. 137-144.
@article{c6d0d9b524cb40aebc5ae0a4e334b06d,
title = "Peptide YY inhibits pancreatic secretion by inhibiting cholecystokinin release in the dog",
abstract = "Peptide YY inhibits the pancreatic exocrine secretion (bicarbonate, water, and protein) that is stimulated by cholecystokinin, secretin, or neurotensin in the dog, but whether peptide YY inhibits the release of gut peptides that stimulate pancreatic exocrine secretion is not known. Six dogs were prepared with gastric, pancreatic, and cecal cannulas. On separate days, a single dose of sodium oleate (3, 6, 7.5, 9, 12, 15, or 18 mmol/h) was given intraduodenally for 90 min, either alone (control) or in combination with peptide YY (25, 50, 100, 200, or 400 pmol/kg · h, i.v.). We measured plasma levels of cholecystokinin- 33 39, secretin, neurotensin, and peptide YY by radioimmunoassay. During infusion of peptide YY, the integrated release of cholecystokinin (3.3 ± 0.5 ng-[0-90] min/ml) was decreased significantly (p < 0.05) when compared with control values (5.6 ± 0.6). Release of secretin and neurotensin was not affected. A positive correlation (p < 0.05) was found between the release of cholecystokinin and pancreatic protein output in both control (r = 0.68) and peptide YY-treated (r = 0.67) groups. Release of peptide YY was significant after intraduodenal or intracolonic administration of sodium oleate. These studies demonstrate that inhibition of pancreatic protein secretion by peptide YY in dogs is mediated, at least in part, by an inhibition of the release of cholecystokinin.",
author = "Felix Lluis and Guillermo Gomez and Masaki Fujimura and Greeley, {George H.} and Thompson, {James C.}",
year = "1988",
language = "English (US)",
volume = "94",
pages = "137--144",
journal = "Gastroenterology",
issn = "0016-5085",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - Peptide YY inhibits pancreatic secretion by inhibiting cholecystokinin release in the dog

AU - Lluis, Felix

AU - Gomez, Guillermo

AU - Fujimura, Masaki

AU - Greeley, George H.

AU - Thompson, James C.

PY - 1988

Y1 - 1988

N2 - Peptide YY inhibits the pancreatic exocrine secretion (bicarbonate, water, and protein) that is stimulated by cholecystokinin, secretin, or neurotensin in the dog, but whether peptide YY inhibits the release of gut peptides that stimulate pancreatic exocrine secretion is not known. Six dogs were prepared with gastric, pancreatic, and cecal cannulas. On separate days, a single dose of sodium oleate (3, 6, 7.5, 9, 12, 15, or 18 mmol/h) was given intraduodenally for 90 min, either alone (control) or in combination with peptide YY (25, 50, 100, 200, or 400 pmol/kg · h, i.v.). We measured plasma levels of cholecystokinin- 33 39, secretin, neurotensin, and peptide YY by radioimmunoassay. During infusion of peptide YY, the integrated release of cholecystokinin (3.3 ± 0.5 ng-[0-90] min/ml) was decreased significantly (p < 0.05) when compared with control values (5.6 ± 0.6). Release of secretin and neurotensin was not affected. A positive correlation (p < 0.05) was found between the release of cholecystokinin and pancreatic protein output in both control (r = 0.68) and peptide YY-treated (r = 0.67) groups. Release of peptide YY was significant after intraduodenal or intracolonic administration of sodium oleate. These studies demonstrate that inhibition of pancreatic protein secretion by peptide YY in dogs is mediated, at least in part, by an inhibition of the release of cholecystokinin.

AB - Peptide YY inhibits the pancreatic exocrine secretion (bicarbonate, water, and protein) that is stimulated by cholecystokinin, secretin, or neurotensin in the dog, but whether peptide YY inhibits the release of gut peptides that stimulate pancreatic exocrine secretion is not known. Six dogs were prepared with gastric, pancreatic, and cecal cannulas. On separate days, a single dose of sodium oleate (3, 6, 7.5, 9, 12, 15, or 18 mmol/h) was given intraduodenally for 90 min, either alone (control) or in combination with peptide YY (25, 50, 100, 200, or 400 pmol/kg · h, i.v.). We measured plasma levels of cholecystokinin- 33 39, secretin, neurotensin, and peptide YY by radioimmunoassay. During infusion of peptide YY, the integrated release of cholecystokinin (3.3 ± 0.5 ng-[0-90] min/ml) was decreased significantly (p < 0.05) when compared with control values (5.6 ± 0.6). Release of secretin and neurotensin was not affected. A positive correlation (p < 0.05) was found between the release of cholecystokinin and pancreatic protein output in both control (r = 0.68) and peptide YY-treated (r = 0.67) groups. Release of peptide YY was significant after intraduodenal or intracolonic administration of sodium oleate. These studies demonstrate that inhibition of pancreatic protein secretion by peptide YY in dogs is mediated, at least in part, by an inhibition of the release of cholecystokinin.

UR - http://www.scopus.com/inward/record.url?scp=0023835244&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023835244&partnerID=8YFLogxK

M3 - Article

C2 - 3335285

AN - SCOPUS:0023835244

VL - 94

SP - 137

EP - 144

JO - Gastroenterology

JF - Gastroenterology

SN - 0016-5085

IS - 1

ER -